Evaluation of IL-10 and TGF-beta levels and myeloid and lymphoid dendritic cells in ovarian cancer patients

Ginekologia Polska

Volumn 82, Issue 6, 2011, Pages 414-420

  Iwona, Wertel ^a   Grzegorz, Polak ^a   Rafał, Tarkowski ^a   Maria, Kotarska ^b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b UNIVERSITY OF NEVADA   (United States)

Author keywords

Dentritic cell; IL 10; Ovarian cancer; TGF beta

Indexed keywords

EID: 79960344058     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Schuler G, Schuler-Thurner B, Steinman R. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol. 2003, 15, 138-147.
2. Bennaceur K, Chapman J, Touraine J, Portoukalian J. Immunosuppressive networks in the tumor environment and their effect in dendritic cells. Biochim Biophys Acta. 2009, 795, 16-24.
3. Zhou J, Ye F, Chen H, et al. The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines. J Int Med Res. 2007, 35, 90-300.
4. Rabinovich A, Medina L, Piura B, Huleihel M. Expression of IL-10 in human normal and cancerous ovarian tissues and cells. Eur Cytokine Netw. 2010, 21, 122-128.
5. Berchuck A, Rodriguez G, Olt G, et al. Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta. Am J Obstet Gynecol. 1992, 166, 676-684.
6. Toutirais O, Chartier P, Dubois D, et al. Constitutive expression of TGF-beta1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma. Eur Cytokine Netw. 2003, 14, 246-255.
7. Santin A, Hermonat P, Ravaggi A, et al. Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol. 1999, 20, 177-181.
8. Offner F, Obrist P, Stadlmann S, et al. IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells. Cytokine. 1995, 7, 542-547.
9. Almand B, Clark J, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001, 166, 78-689.
10. Wertel I, Polak G, Barczyński B, Kotarski J. Subpopulacje komórek dendrytycznych krwi obwodowej w przebiegu chemioterapii raka jajnika. Ginekol Pol. 2007, 78, 768-71.
11. Torres-Aguilar H, Aguilar-Ruiz S, González-Pérez G, et al. Tolerogenic dendritic cells generated with different immunosuppressive cytokines induce antigen-specific anergy and regulatory properties in memory CD4+ T cells. J Immunol. 2010, 184, 1765-1775.
12. Gregori S, Tomasoni D, Pacciani V, et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenie DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood. 010, 116, 935-944.
13. Sato K, Yamashita N, Baba M, Matsuyama T. Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood. 2003, 101, 581-3589.
14. Wertel I, Polak G, Bednarek W, et al. Dendritic cell subsets in the peritoneal fluid and peripheral blood of women suffering from ovarian cancer. Cytometry B Clin Cytom. 2008, 74, 251-258.
15. Fricke I, Gabrilovich D. Dendritic cells and tumor microenvironment: a dangerous liaison. Immunol Invest. 2006, 35, 459-483.
16. Menetrier-Caux C, Montmain G, Dieu M, et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colonystimulating factor. Blood. 1998, 92, 4778-4791.
17. Gabrilovich D, Chen H, Girgis K, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996, 2, 1096-1103. Nat Med. 1996, 2, 1096-1103.
18. Santin A, Bellone S, Ravaggi A, et al. Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer. BJOG. 2001, 108, 804-808.
19. Mustea A, Könsgen D, Braicu E, et al. Expression of IL-10 in patients with ovarian carcinoma. Anticancer Res. 2006, 26, 1715-1718.
20. Ancuta P, Weiss L, Haeffner-Cavaillon N. CD14+CD16++ cells derived in vitro from peripheral blood monocytes exhibit phenotypic and functional dendritic cell-like characteristics. Eur J Immunol. 2000, 30, 1872-1883.
21. Liu V, Wong L, Jang T, et al. Tumor evasion of the immune system by converting CD4+CD25-T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol. 2007, 178, 2883-2892.
22. Allavena P, Piemonti L, Longoni D, et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol. 1998, 8, 359-369.
23. Velten F, Duperrier K, Bohlender J, et al. A gene signature of inhibitory MHC receptors identifies a BDCA3(+) subset of IL-10-induced dendritic cells with reduced allostimulatory capacity in vitro. Eur J Immunol. 2004, 34, 2800-2811.
24. Groux H, Bigler M, de Vries J, Roncarlo M. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med. 1996, 184, 19-29.
25. Curiel T, Cheng P, Mottram P, et al. Dendritic cells subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res. 2004, 64, 5535-5538.
26. Yamaguchi Y, Tsumura H, Miwa M, Inaba K. Contrasting effects of TGF-beta 1 and TNF-alpha on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells. 1997, 15, 144-153.
27. Alard P, Clark S, Kosiewicz M, et al. Mechanisms of tolerance induced by TGF beta-treated APC: CD4 regulatory T cells prevent the induction of the immune response possibly through a mechanism involving TGF beta. Eur J Immunol. 2004, 34, 1021-1030.
28. Chen L, Ye F, Lü W, et al. Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma. J Obstet Gynaecol Res. 2009, 35, 212-218.